FMP
Inhibrx Biosciences, Inc.
INBX
NASDAQ
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
14.1 USD
-0.05 (-0.355%)
Historical Prices
From:
To:
About
Description
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothe...
CIK
0001739614
ISIN
US45720L1070
CUSIP
45720L107
Address
11025 North Torrey Pines Road
Phone
858-795-4220
Country
US
Employee
166
IPO Date
Jun 4, 2024
Financial Statement
Earnings
INBX Financial Summary
CIK
0001739614
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
45720L107
ISIN
US45720L1070
Country
US
Price
14.1
Beta
-1.11
Volume Avg.
92.18k
Market Cap
204.11M
Shares
-
52-Week
10.8-18.95
DCF
1.06
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
0.12
P/B
-
Website
https://inhibrx.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest INBX News
Seeking Alpha
Jun 7, 2024
Inhibrx: Continued Advancement Even After INBRX-101 Sale To ...
Inhibrx Biosciences, Inc.'s INBRX-109 is a tetravalent drug being developed for the treatment of patients with Ewing Sarcoma and other solid tumor types. It is expected that the Ewing Sarcoma Therapeutics market size could be worth as much as $424.42 million by 2032. INBRX-106 is a hexavalent drug being developed for the treatment of patients with multiple solid tumor types.
Benzinga
Jun 5, 2024
Top 4 Health Care Stocks That Are Preparing To Pump This Mon...
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Zacks Investment Research
Feb 28, 2024
Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates
Inhibrx, Inc. (INBX) came out with a quarterly loss of $1.73 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $0.95 per share a year ago.
Zacks Investment Research
Jan 24, 2024
Inhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in t...
Inhibrx, Inc. (INBX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks Investment Research
Jan 23, 2024
Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi
Sanofi (SNY) will acquire Inhibrx (INBX) for nearly $2.2 billion. Post-acquisition, it will retain the rare disease drug and spin out all other pipeline programs into a newly-traded public company.
Investopedia
Jan 23, 2024
Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare...
Inhibrx (INBX) shares jumped over 7% in early trading Tuesday after Sanofi (SNY) said it would buy Inhibrx in a $1.7 billion deal as the French pharmaceutical giant expands its pipeline of drugs to treat rare diseases.
GuruFocus
Sep 1, 2023
Andreas Halvorsen's Firm Ups Inhibrx Stake
Viking Global Investors, the investment firm founded by Andreas Halvorsen (Trades, Portfolio) in 1999, disclosed earlier this week it boosted its stake in Inhibrx Inc. ( INBX , Financial) by 7.71% following a private placement financing agreement.
Seeking Alpha
Aug 17, 2023
Inhibrx: INBRX-101 Developments Constructive, Market-Generat...
INBX is researching a breakthrough for Alpha-1 Antitrypsin deficiency and has received regulatory support for its INBRX-101 pipeline. The AATD treatment market is expected to experience robust growth in the coming years. INBRX-101 has received Fast Track designation from the FDA for the treatment of emphysema.
